• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Global Testicular Cancer Drugs Market 2014-2018 - Product Image

Global Testicular Cancer Drugs Market 2014-2018

  • ID: 2757635
  • January 2014
  • Region: Global
  • 52 Pages
  • TechNavio

FEATURED COMPANIES

  • Bristol-Myers Squibb Co.
  • Hospira Inc.
  • ZIOPHARM Oncology Inc.
  • MORE

The analysts forecast the Global Testicular Cancer Drugs market to grow at a CAGR of 4.02 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increasing incidence of testicular cancer. The Global Testicular Cancer Drugs market has also been witnessing the emergence of combination therapies for the treatment of testicular cancer. However, the presence of alternative testicular cancer treatments could pose a challenge to the growth of this market.

The report, the Global Testicular Cancer Drugs Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market market in the Americas, and the EMEA and APAC regions; it also covers the Global Testicular Cancer Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors dominating this space include Bristol-Myers Squibb Co., Hospira Inc., Teva Pharmaceutical Industries Ltd., and ZIOPHARM Oncology Inc.

Other vendors mentioned in the report are Baxter International Inc., Fresenius Kabi Pharmaceuticals READ MORE >

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Bristol-Myers Squibb Co.
  • Hospira Inc.
  • ZIOPHARM Oncology Inc.
  • MORE

01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast
06.3 Five Forces Analysis
07. Testicular Cancer by Type
07.1.1 Seminoma
07.1.2 Non-seminoma
08. Testicular Cancer Disease by Stages
08.1.1 Stage 0
08.1.2 Stage I
08.1.3 Stage II
08.1.4 Stage III
09. Treatment Options
09.1 Surgery
09.2 Radiation Therapy
09.3 Chemotherapy
10. Clinical Trial Snapshot
11. Geographical Segmentation
11.1 Global Testicular Cancer Drugs Market by Geographical Segmentation
12. Buying Criteria
13. Rate of Incidence and Prevalence
14. Market Growth Drivers
15. Drivers and their Impact
16. Market Challenges
17. Impact of Drivers and Challenges
18. Market Trends
19. Trends and their Impact
20. Vendor Landscape
20.1 Competitive Scenario
20.1.1 Key News
20.1.2 Acquisitions
20.2 Other Prominent Vendors
21. Key Vendor Analysis
21.1 Bristol-Myers Squibb Co.
21.1.1 Business Overview
21.1.2 Key Information
21.1.3 SWOT Analysis
21.2 Hospira Inc.
21.2.1 Business Overview
21.2.2 Business Segmentation
21.2.3 Key Information
21.2.4 SWOT Analysis
21.3 Teva Pharmaceutical Industries Ltd.
21.3.1 Business Overview
21.3.2 Business Segmentation
21.3.3 Key Information
21.3.4 SWOT Analysis
21.4 ZIOPHARM Oncology Inc.
21.4.1 Business Overview
21.4.2 Key Information
21.4.3 SWOT Analysis
22. Other Reports in this Series

List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Global Testicular Cancer Drugs market 2013-2018 (US$ million)
Exhibit 3: Testicular Cancer Segmentation by Type
Exhibit 4: Global Testicular Cancer Drugs Market by Geographical Segmentation 2013 (percent)
Exhibit 5: Business Segmentation of Hospira Inc.
Exhibit 6: Business Segmentation of Teva Pharmaceutical Industries Ltd.

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Bristol-Myers Squibb Co.
  • Hospira Inc.
  • ZIOPHARM Oncology Inc.
  • MORE

Commenting on the report, an analyst from the team said: “The current trend witnessed by the Global Testicular Cancer Drugs market is combination therapy being used for treating testicular cancer. Several oncologists believe that chemotherapy drugs are most effective when given in combination with radiation therapy and surgery. Cancer cells that are confined locally can be easily treated by surgery or radiation therapy, while cancer cells that have spread to distant sites can be killed by chemotherapy. Therefore, combination therapy helps in completely removing the tumor or destroying the cancerous cells in the patient's body. The combination therapy is decided depending on the size of the tumor and the risk of recurrence. Moreover, for treatment of testicular cancer, a combination of two or more drugs is usually given. Some of the combinations are BEP, EP (etoposide and cisplatin), and VIP (vinblastine plus ifosfamide and cisplatin).”

According to the report, one of the key drivers is the increasing prevalence of testicular cancer due to a variety of factors such as congenital abnormalities, family history, abnormal testicular development, and HIV infection. This has increased the demand for testicular cancer drugs as these drugs have greatly improved survival rate for patients with both seminomas and non-seminomas type of testicular cancer.

Further, the report states that one of the main challenges in the market is the presence of alternative testicular cancer treatments that do not use drugs, thereby limiting the consumption of drugs.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

Note: Product cover images may vary from those shown

- Bristol-Myers Squibb Co.
- Hospira Inc.
- Teva Pharmaceutical Industries Ltd.
- ZIOPHARM Oncology Inc.

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos